Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Holiday Inn London Kensington Forum

Oct 29, 2018 7:30 AM - Oct 30, 2018 12:00 PM

97 Cromwell Road, London, SW7 4DN, United Kingdom

A Comprehensive Review of Regulatory Procedures for Investigational New Drugs (INDs) in the US

This course is designed for persons with a novice to intermediate experience in Regulatory Affairs, who need knowledge of the US IND Application regulatory processes.

Faculty

Carol H. Danielson, DrPH, MS, RAC

Carol H. Danielson, DrPH, MS, RAC

President, Regulatory Advantage, LLC, United States

Ms Carol H. Danielson, Dr PH, RAC has provided regulatory expertise and leadership for more than twenty five years for drugs, biologics and medical devices from discovery through post-marketing. Her areas of specialization include regulatory strategy and submissions, clinical affairs and compliance, and quality assurance and control. Her background includes both extensive “hands on” experience and corporate level strategy activities from partnering due diligence to serving as an expert witness in the drug development process.

Michael  Hamrell, PhD, RAC

Michael Hamrell, PhD, RAC

President, MORIAH Consultants, United States

Dr. Michael R. Hamrell is the President of MORIAH Consultants, a Regulatory Affairs/Clinical Research consulting firm located near Los Angeles, CA. He has worked in pharmaceuticals, contract research, government and biotech industries, in domestic and international regulatory affairs and clinical research. He also worked in the Division of AIDS in NIAID at NIH and as a reviewer at CDER at the FDA. Dr. Hamrell has published numerous papers in pharmacology, regulatory affairs, product development, clinical research, computers and information systems.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.